FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306736751> ?p ?o ?g. }

• W4306736751 endingPage "5095" @default.
• W4306736751 startingPage "5095" @default.
• W4306736751 abstract "Background: Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in non-small cell lung cancer (NSCLC). However, the efficacy of osimertinib in patients without acquired T790M mutations has not been well studied. This study aimed to evaluate the efficacy of osimertinib in patients treated with first- and second-generation EGFR-TKIs followed by later-line osimertinib treatment. Patients: The clinical data and survival outcomes of 172 patients with advanced NSCLC treated with osimertinib following frontline EGFR-TKIs at Chang Gung Memorial Hospital from 2014 to 2018 were retrospectively reviewed. T790M mutations were detected using tissue sequencing and/or liquid biopsy. Results: A total of 172 EGFR-mutated NSCLC patients treated with frontline EGFR-TKI therapy followed by later-line osimertinib were enrolled in the current study and divided into three groups based on the T790M status (positive, negative, or unknown T790M). Patients with NSCLC harboring acquired T790M mutation treated with osimertinib had the best objective response rate (ORR) (52.6%, 25.0%, and 32.0%, p = 0.044), disease control rate (DCR) (79.3%, 41.7%, and 68.0%, p = 0.011), and progression-free survival (PFS, median PFS, 12.6, 3.1, 10.4 months, p = 0.001) among the three groups (positive, negative, and unknown T790M, respectively). However, a marked difference was found between positive and negative T790M mutations but not between positive and unknown T790M mutations. Univariate analysis was performed to identify potential prognostic factors for PFS in 172 patients treated with osimertinib. Lung metastasis (p < 0.001), brain metastasis (p < 0.009), number of metastatic sites (p < 0.001), PFS with frontline EGFR-TKIs (p = 0.03), and T790M status (p = 0.006) were identified as prognostic factors for PFS with osimertinib. Multivariate analysis showed that lung metastasis (p < 0.001) and PFS with frontline EGFR-TKIs and T790M status were independent prognostic factors. Conclusion: This study confirmed the greater efficacy of later-line osimertinib for NSCLC with acquired T790M mutation than for NSCLC without acquired T790M mutation. Detection of the T790M mutation after frontline treatment (first- and second-generation EGFR-TKI) is crucial for prolonging the survival of NSCLC patients harboring EGFR mutation. Osimertinib may be considered an option for NSCLC with unknown T790M mutations, as a certain subpopulation may benefit from osimertinib." @default.
• W4306736751 created "2022-10-19" @default.
• W4306736751 creator A5009721499 @default.
• W4306736751 creator A5030540923 @default.
• W4306736751 creator A5031425147 @default.
• W4306736751 creator A5031628450 @default.
• W4306736751 creator A5042893625 @default.
• W4306736751 creator A5054050349 @default.
• W4306736751 creator A5071806965 @default.
• W4306736751 creator A5072713696 @default.
• W4306736751 creator A5088022850 @default.
• W4306736751 date "2022-10-18" @default.
• W4306736751 modified "2023-09-30" @default.
• W4306736751 title "Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients" @default.
• W4306736751 cites W1980497534 @default.
• W4306736751 cites W2003984225 @default.
• W4306736751 cites W2088540000 @default.
• W4306736751 cites W2096198395 @default.
• W4306736751 cites W2111662961 @default.
• W4306736751 cites W2125665528 @default.
• W4306736751 cites W2132157071 @default.
• W4306736751 cites W2138089710 @default.
• W4306736751 cites W2154149901 @default.
• W4306736751 cites W2163351155 @default.
• W4306736751 cites W2403654892 @default.
• W4306736751 cites W2494292000 @default.
• W4306736751 cites W2560717039 @default.
• W4306736751 cites W2888877308 @default.
• W4306736751 cites W2902378590 @default.
• W4306736751 cites W2907814135 @default.
• W4306736751 cites W2953884587 @default.
• W4306736751 cites W2976334328 @default.
• W4306736751 cites W3011476556 @default.
• W4306736751 cites W3044968314 @default.
• W4306736751 cites W3082994084 @default.
• W4306736751 cites W3093100177 @default.
• W4306736751 cites W3185413675 @default.
• W4306736751 cites W3190668477 @default.
• W4306736751 cites W3200767196 @default.
• W4306736751 cites W3204380660 @default.
• W4306736751 cites W4213063929 @default.
• W4306736751 cites W4213258495 @default.
• W4306736751 cites W4220828320 @default.
• W4306736751 cites W4281929609 @default.
• W4306736751 doi "https://doi.org/10.3390/cancers14205095" @default.
• W4306736751 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36291877" @default.
• W4306736751 hasPublicationYear "2022" @default.
• W4306736751 type Work @default.
• W4306736751 citedByCount "3" @default.
• W4306736751 countsByYear W43067367512022 @default.
• W4306736751 countsByYear W43067367512023 @default.
• W4306736751 crossrefType "journal-article" @default.
• W4306736751 hasAuthorship W4306736751A5009721499 @default.
• W4306736751 hasAuthorship W4306736751A5030540923 @default.
• W4306736751 hasAuthorship W4306736751A5031425147 @default.
• W4306736751 hasAuthorship W4306736751A5031628450 @default.
• W4306736751 hasAuthorship W4306736751A5042893625 @default.
• W4306736751 hasAuthorship W4306736751A5054050349 @default.
• W4306736751 hasAuthorship W4306736751A5071806965 @default.
• W4306736751 hasAuthorship W4306736751A5072713696 @default.
• W4306736751 hasAuthorship W4306736751A5088022850 @default.
• W4306736751 hasBestOaLocation W43067367511 @default.
• W4306736751 hasConcept C121608353 @default.
• W4306736751 hasConcept C126322002 @default.
• W4306736751 hasConcept C143998085 @default.
• W4306736751 hasConcept C2776256026 @default.
• W4306736751 hasConcept C2777626846 @default.
• W4306736751 hasConcept C2777930144 @default.
• W4306736751 hasConcept C2778087573 @default.
• W4306736751 hasConcept C2779438470 @default.
• W4306736751 hasConcept C2780580887 @default.
• W4306736751 hasConcept C71924100 @default.
• W4306736751 hasConceptScore W4306736751C121608353 @default.
• W4306736751 hasConceptScore W4306736751C126322002 @default.
• W4306736751 hasConceptScore W4306736751C143998085 @default.
• W4306736751 hasConceptScore W4306736751C2776256026 @default.
• W4306736751 hasConceptScore W4306736751C2777626846 @default.
• W4306736751 hasConceptScore W4306736751C2777930144 @default.
• W4306736751 hasConceptScore W4306736751C2778087573 @default.
• W4306736751 hasConceptScore W4306736751C2779438470 @default.
• W4306736751 hasConceptScore W4306736751C2780580887 @default.
• W4306736751 hasConceptScore W4306736751C71924100 @default.
• W4306736751 hasIssue "20" @default.
• W4306736751 hasLocation W43067367511 @default.
• W4306736751 hasLocation W43067367512 @default.
• W4306736751 hasLocation W43067367513 @default.
• W4306736751 hasLocation W43067367514 @default.
• W4306736751 hasOpenAccess W4306736751 @default.
• W4306736751 hasPrimaryLocation W43067367511 @default.
• W4306736751 hasRelatedWork W2560717039 @default.
• W4306736751 hasRelatedWork W2921871143 @default.
• W4306736751 hasRelatedWork W2944067375 @default.
• W4306736751 hasRelatedWork W3000070469 @default.
• W4306736751 hasRelatedWork W3036162643 @default.
• W4306736751 hasRelatedWork W3175026159 @default.
• W4306736751 hasRelatedWork W3185869221 @default.
• W4306736751 hasRelatedWork W4210464383 @default.
• W4306736751 hasRelatedWork W4220695811 @default.

• next